Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thil D. Batuwangala"'
Autor:
Lasse Stach, Emily K. H. Dinley, Nadia Tournier, Ryan P. Bingham, Darren A. Gormley, Jo L. Bramhall, Adam Taylor, Jane E. Clarkson, Katherine A. Welbeck, Claire L. Harris, Maria Feeney, Jane P. Hughes, Armin Sepp, Thil D. Batuwangala, Semra J. Kitchen, Eva-Maria Nichols
Publikováno v:
Antibodies, Vol 10, Iss 4, p 39 (2021)
The terminal pathway of complement is implicated in the pathology of multiple diseases and its inhibition is, therefore, an attractive therapeutic proposition. The practicalities of inhibiting this pathway, however, are challenging, as highlighted by
Externí odkaz:
https://doaj.org/article/9c08d3afb4f34afc913b99f6d81d4c48
Autor:
Jane E Clarkson, Nadia Tournier, Ryan P. Bingham, Maria Feeney, Semra Kitchen, Jo L Bramhall, Darren A. Gormley, Lasse Stach, Eva-Maria Nichols, Jane P. Hughes, Katherine A Welbeck, Claire L. Harris, Adam Taylor, Armin Sepp, Thil D. Batuwangala, Emily K H Dinley
Publikováno v:
Antibodies, Vol 10, Iss 39, p 39 (2021)
Antibodies
Volume 10
Issue 4
Antibodies
Volume 10
Issue 4
The terminal pathway of complement is implicated in the pathology of multiple diseases and its inhibition is, therefore, an attractive therapeutic proposition. The practicalities of inhibiting this pathway, however, are challenging, as highlighted by
Autor:
Martin J. Scott, Ian Hiles, Matthew S. Wake, Claire Ashman, Michael Steward, Trevor Anthony Kenneth Wattam, Thil D. Batuwangala, Kelly V. Batt, Jennifer A. Lee
Publikováno v:
mAbs. 9:85-93
Bispecific antibodies (BsAbs) are emerging as an important class of biopharmaceutical. The majority of BsAbs are created from conventional antibodies or fragments engineered into more complex configurations. A recurring challenge in their development
Publikováno v:
Current Opinion in Biotechnology. 20:405-411
Most therapeutic antibodies in the clinic today are based on fully humanised immunoglobulins. They have proven to be outstandingly effective, especially for the treatment of cancer, autoimmune and inflammatory diseases where the target is a single, w